The Full-Year Continuing Appropriations and Extensions Act of 2025 provides $650 million in funding for the Congressionally Directed Medical Research Programs (The Cancer Letter, March 28, 2025). Congress provided further guidance for CDMRP program-level funding, including funding for the Rare Cancers Research Program.
The American Association for Cancer Research has established the AACR Trailblazer Cancer Research Grant Program.
The American Association for Cancer Research-Novocure Career Development Award for Cancer Research represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field.
The Stephenson Global Pancreatic Cancer Research Institute, established to advance early detection, innovative treatments, and groundbreaking research for pancreatic cancer, has launched a call for nominations and Letters of Intent for two award opportunities.
Global research initiative Cancer Grand Challenges announced on March 5 seven new challenges which it deems to be among the biggest questions in cancer, offering international researchers the chance to form teams to apply for up to $25 million (or £20 million) in funding to take them on.
The FY25 Defense Appropriations Act is anticipated to provide funding for the Peer Reviewed Cancer Research Program to support innovative, high-impact cancer research.
The FY25 Defense Appropriations Act is anticipated to provide funding for the Melanoma Research Program to support innovative, high-impact melanoma research.
The Stephenson Global Pancreatic Cancer Research Institute is creating new awards to advance pancreatic cancer research.
The FY25 Defense Appropriations Act is anticipated to provide funding for the Ovarian Research Program to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members and all women impacted by this disease. The Congressionally Directed Medical Research Programs, or CDMRP, at the U.S. Army Medical Research and Development Command is the program office managing these anticipated FY25 funding opportunities.
The FY24 Defense Appropriations Act provides funding for the Glioblastoma Research Program to support research of high potential impact and exceptional scientific merit to reduce the burden of glioblastoma on service members and their families, veterans, and the American public. The managing agent for the anticipated program announcements/funding opportunities is the CDMRP at the U.S. Army Medical Research and Development Command.
